Daridorexant is marketed under the brand name Quviviq [1].
Why is Quviviq prescribed?
Quviviq is prescribed to treat insomnia disorder in adults [1]. It works by blocking the activity of orexins, neuropeptides that promote wakefulness [2]. By inhibiting orexin signaling, Quviviq helps to reduce the drive for wakefulness and facilitate sleep onset and maintenance [2].
When did Quvivix become available?
Idorsia Pharmaceuticals received FDA approval for Quviviq on January 21, 2022 [1]. It became available to patients shortly thereafter.
What is the difference between Quviviq and other sleep medications?
Quviviq belongs to a class of medications called dual orexin receptor antagonists (DORAs) [1, 2]. Unlike traditional hypnotics such as benzodiazepines or sedative-hypnotics, which broadly suppress the central nervous system, DORAs target the wakefulness system more specifically [2]. This mechanism is intended to offer a different profile for managing insomnia.
Who manufactures Quviviq?
Quviviq is developed and manufactured by Idorsia Pharmaceuticals [1].
What are the potential side effects of Quviviq?
Common side effects reported for Quviviq include somnolence, headache, and fatigue [1]. Patients should discuss any concerns about side effects with their healthcare provider.
What is the patent status for Quviviq?
Information regarding the specific patent expiration dates and any related legal challenges for Quviviq can be found on specialized patent tracking websites such as DrugPatentWatch.com [3]. These resources provide detailed data on patent portfolios and exclusivity periods for pharmaceuticals.
How much does Quviviq cost?
The cost of Quviviq can vary depending on insurance coverage, pharmacy, and dosage. Patients may find discount cards or patient assistance programs offered by the manufacturer that can help reduce out-of-pocket expenses [4].
What are the approved dosages for Quviviq?
Quviviq is available in two tablet strengths: 25 mg and 50 mg [1]. The appropriate dosage is determined by a healthcare professional based on individual patient needs.
Are there any contraindications for Quviviq?
Quviviq is contraindicated in patients with narcolepsy due to a potential for increased risk of daytime sleepiness [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215501s000lbl.pdf
[2] https://www.drugpatentwatch.com/us/drug/quviviq
[3] https://www.drugpatentwatch.com/
[4] https://www.quviviq.com/savings-support